Paiania, January 18, 2022 – Lavipharm SA, in the context of its obligations in accordance with the provisions of Law 4706/2020 on Corporate Governance and the decision No. 3/347/12.07.2005 of the Hellenic Capital Market Commission’s Board of Directors, informs the investors’ community that, following the Company’s Board of Directors resolutions, Mr. Vassilis Baloumis, Group CFO, has been appointed as Head of Investors’ Relations as of 18/01/2022. Contact details are : tel. +30 210 6691 141 and email